Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 12/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18528829 | 0.84 | PTGDR2 (0.60) | PTGDR2MAPTL3MBTL1GLAMEN1 | |
| SCHEMBL21313903 | 0.83 | PTGDR2 (0.63) | PTGDR2 | |
| SCHEMBL10419985 | 0.82 | PTGDR2 (0.62) | PTGDR2MAPTMEN1KMT2A | |
| SCHEMBL3951141 | 0.81 | PTGDR2 (0.67) | PTGDR2AKR1B1 | |
| SCHEMBL16741187 | 0.80 | PTGDR2 (0.66) | PTGDR2AKR1B1 | |
| SCHEMBL6071781 | 0.80 | PTGDR2 (0.63) | PTGDR2AKR1B1MGLL | |
| SCHEMBL2771927 | 0.80 | PTGDR2 (0.63) | PTGDR2AKR1B1 | |
| SCHEMBL1371244 | 0.80 | PTGDR2 (0.63) | PTGDR2AKR1B1 | |
| SCHEMBL18528835 | 0.79 | PTGDR2 (0.60) | PTGDR2L3MBTL1GLAAKR1B1MGLL | |
| SCHEMBL16962740 | 0.79 | PTGDR2 (0.63) | PTGDR2AKR1B1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200199155-A1 | CONDENSED [1,4] DIAZEPINE COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-06-25 | — | — | US | disclosed |
| US-20200199155-A1 | CONDENSED [1,4] DIAZEPINE COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-06-25 | — | — | US | disclosed |
| US-10669285-B2 | Condensed [1,4] diazepine compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-10669285-B2 | Condensed [1,4] diazepine compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-06-02 | — | — | US | disclosed |
| EP-3122751-B1 | CONDENSED [1,4]DIAZEPINE COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-10-30 | — | — | EP | disclosed |
| EP-3122751-B1 | CONDENSED [1,4]DIAZEPINE COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-10-30 | — | — | EP | disclosed |
| EP-3122751-A1 | CONDENSED [1,4]DIAZEPINE COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2017-02-01 | — | — | EP | disclosed |
| US-20170008913-A1 | CONDENSED [1,4] DIAZEPINE COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008913-A1 | CONDENSED [1,4] DIAZEPINE COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008913-A1 | CONDENSED [1,4] DIAZEPINE COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2017-01-12 | — | — | US | disclosed |
| WO-2015144609-A1 | CONDENSED [1,4]DIAZEPINE COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-10-01 | — | — | WO | disclosed |
| WO-2015144609-A1 | CONDENSED [1,4]DIAZEPINE COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669285-B2 | Condensed [1,4] diazepine compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors | LPAR1, ENPP2, LPCAT1 | PTGDR2 789/4885MAPT 2372/4885L3MBTL1 2516/4885 |
| US-20170008913-A1 | CONDENSED [1,4] DIAZEPINE COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | LPAR1, ENPP2, LPCAT1 | PTGDR2 789/4885MAPT 2372/4885L3MBTL1 2516/4885 |
| US-20200199155-A1 | CONDENSED [1,4] DIAZEPINE COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | LPAR1, ENPP2, LPCAT1 | PTGDR2 789/4885MAPT 2372/4885L3MBTL1 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.